Igor José dos Santos Nascimento
◽
Thiago Mendonça de Aquino
◽
Edeildo Ferreira da Silva-Júnior
Background:
Viral diseases are responsible for several deaths around the world. Over the past few years, the world has seen several
outbreaks caused by viral diseases that for a long time seemed to possess no risk. These are diseases that have been forgotten for a long time
and, until nowadays, there are no approved drugs or vaccines, leading the pharmaceutical industry and several research groups to run out of time
in the search for new pharmacological treatments or prevention methods. In this context, drug repurposing proves to be a fast and economically
viable technique, considering the fact that it uses drugs that have a well-established safety profile. Thus, in this review, we present the main advances in drug repurposing and their benefit for searching new treatments against emerging viral diseases.
Methods:
We conducted a search in the bibliographic databases (Science Direct, Bentham Science, PubMed, Springer, ACS Publisher, Wiley,
and NIH’s COVID-19 Portfolio) using the keywords "drug repurposing", "emerging viral infections" and each of the diseases reported here
(CoV; ZIKV; DENV; CHIKV; EBOV and MARV) as an inclusion/exclusion criterion. A subjective analysis was performed regarding the quality of the works for inclusion in this manuscript. Thus, the selected works were those that presented drugs repositioned against the emerging viral diseases presented here by means of computational, high-throughput screening or phenotype-based strategies, with no time limit and of relevant scientific value.
Results:
291 papers were selected, 24 of which were CHIKV; 52 for ZIKV; 43 for DENV; 35 for EBOV; 10 for MARV; and 56 for CoV and
the rest (72 papers) related to the drugs repurposing and emerging viral diseases. Among CoV-related articles, most were published in 2020 (31
papers), updating the current topic. Besides, between the years 2003 - 2005, 10 articles were created, and from 2011 - 2015 there were 7 articles,
portraying the outbreaks that occurred at that time. For ZIKV, similar to CoV, most publications were during the period of outbreaks between
the years 2016 - 2017 (23
articles). Similarly, most CHIKV (13 papers) and DENV (14 papers) publications occur at the same time interval. For EBOV (13 papers) and
MARV (4 papers), they were between the years 2015 - 2016. Through this review, several drugs were highlighted that can be evolved in vivo
and clinical trials as possible used against these pathogens showed that remdesivir represent potential treatments against CoV. Furthermore, ribavirin may also be a potential treatment against CHIKV; sofosbuvir against ZIKV; celgosivir against DENV, and favipiravir against EBOV and
MARV, representing new hopes against these pathogens.
Conclusions:
The conclusions of this review manuscript show the potential of the drug repurposing strategy in the discovery of new pharmaceutical products, as from this approach, drugs that could be used against emerging viral diseases. Thus, this strategy deserves more attention
among research groups and is a promising approach to the discovery of new drugs against emerging viral diseases and also other diseases.
COVID-19’s impact on travel medicine surpasses that of all other emerging viral diseases